Novo Nordisk Faces a Pivotal Week as Legal Woes and a Failed Heart Drug Trial Cloud the Earnings Horizon

Options signal 8% swing as Novo Nordisk's H1 results loom, with GLP-1 franchise under pressure after Ziltivekimab trial miss and legal battles.

The options market is pricing in fireworks, but the fundamental picture at Novo Nordisk looks anything but celebratory. When the Danish pharmaceutical giant delivers its first-half results on August 5, traders have already positioned for a swing of roughly eight percent in the US-listed shares — a move that would dwarf the market's reaction to either of the company's last two quarterly reports.

That elevated expectation stems from a bruising fortnight that has left the stock nursing wounds on multiple fronts. The shares closed Friday at 40.90 euros in Frankfurt, down 8.48 percent on the session after a fresh bout of selling, and roughly 25 percent below the January peak of 54.86 euros. The seven-day slide now stands at 5.93 percent, with the price hovering almost exactly at its 50-day moving average — a level that technical analysts read as a market searching for direction.

A Double Blow in Three Days

The recent turbulence began on July 28, when a US federal judge allowed parts of a shareholder lawsuit to proceed to discovery. Novo Nordisk's motion to dismiss was denied, leaving the company to defend allegations that it misled investors about the study protocol and tolerability of CagriSema during the REDEFINE-1 trial.

Just three days later came the more consequential setback. Ziltivekimab, the company's cardiovascular candidate, failed to meet its primary endpoint in the late-stage ZEUS study, which had been designed to show a reduction in major adverse cardiovascular events. The miss deals a significant blow to Novo Nordisk's diversification strategy — the molecule was meant to establish the company as a leader in cardiovascular inflammation treatment. Management has insisted the outcome does not alter the previously communicated 2026 profit guidance, though a non-cash impairment charge will land in the third quarter.

The GLP-1 Engine Carries the Weight

With the pipeline setback narrowing the company's strategic optionality, the burden now falls squarely on the GLP-1 franchise — and specifically on the oral formulation of Wegovy. The EU Commission granted marketing approval for the pill on July 15, making it the first oral GLP-1 therapy for weight management in the bloc, a milestone that opens a new front in the obesity wars.

Novo Nordisk has also been playing defense on the commercial side. On July 21, the company announced legal action against Eli Lilly aimed at halting what it describes as misleading national GLP-1 advertising campaigns in the US. The move underscores the intensifying rivalry, which was further inflamed on July 23 when Lilly published positive phase-3 data for its investigational candidate Retatrutide.

Despite the competitive pressure, Novo Nordisk still commands roughly 89 percent of the US oral GLP-1 market by volume since the pill's January launch. The question for the August 5 report is whether that dominance translates into enough growth to offset the loss of Ziltivekimab as a diversification story and the legal overhang surrounding CagriSema.

Analyst Sentiment: A House Divided

The sell-side community appears genuinely split on the company's trajectory. On the Copenhagen-listed B-shares, the consensus among 26 analysts stands at "Hold," with an average price target of 317.20 Danish kroner. The range of individual targets, however, tells a more dramatic story: estimates span from 200 to 453 kroner, a chasm that reflects deep disagreement over the outcome of the obesity race against Lilly.

Across the Atlantic, the picture is marginally more constructive. A broader panel of 37 analysts assigns a 68 percent buy rating, with a mean twelve-month target of 51.19 US dollars.

Expectations have been reset lower in the run-up to the report. Consensus earnings per share estimates have been trimmed by roughly 24 percent over the past year to about 5.02 Danish kroner. That lowered bar could make a positive surprise easier to achieve — though Saxo Bank notes that the options market is still bracing for a reaction larger than the 6.7 percent and 5.4 percent declines that followed the previous two earnings releases.

Two Technical Thresholds

Chartists are watching a pair of levels with particular interest. The stock currently trades just above its 200-day moving average of 40.34 euros, a line that has so far held as support. Holding that level would suggest the recent weakness is a correction rather than a trend reversal, potentially opening a path back toward the 50-day average and, eventually, the 52-week high of 54.86 euros.

A disappointing outlook on August 5 — or evidence of sharper margin compression than anticipated — could break that technical foundation. In that scenario, a retest of the 52-week low of 30.25 euros, a level some 36 percent below the current price, cannot be ruled out.

The stock's year-to-date performance shows a decline of 6.5 percent, though the US listing has actually climbed about 8.7 percent since the first-quarter numbers were released.

What the Market Will Actually Be Listening For

With earnings estimates already cut and a guidance raise widely anticipated — and therefore likely priced in — the market's reaction may hinge less on the headline figures than on management's commentary. Two themes are expected to dominate the call: pricing dynamics in the US market and the pace of the international rollout for the oral Wegovy pill.

Beyond the quarterly numbers, investors have a second date on the calendar. On September 20 and 21, Novo Nordisk hosts its Capital Markets Day, where management is slated to present a full review of long-term strategy, business segments, and financial targets. That event could ultimately carry more weight than the earnings print itself in determining whether the current weakness is a buying opportunity or the beginning of a more prolonged de-rating.

For now, the stock sits in a narrow band between technical support and strategic uncertainty, with the options market signaling that the resolution — whichever way it comes — could be abrupt.